TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3)

Summary

TAC01-CLDN18.2 is a novel cell therapy that consists of genetically engineered autologous T cells expressing T-cell Antigen Coupler (TAC) that recognizes Claudin 18.2. TAC directs T-cells to the targeted antigen (CLDN 18.2), and once engaged with the target, activates them via the endogenous T cell receptor. This is an open-label, multicenter Phase ½ study that aims to establish safety, maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D), pharmacokinetic profile and efficacy of TAC01-CLDN18.2.

Timeline

Start

2023-08-23

Primary completion

2027-08-01

Completion

2027-08-01

Drugs

Indications